▶ 調査レポート

膵臓がん診断の世界市場(~2026年)

• 英文タイトル:Global Pancreatic Cancer Diagnostic Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。膵臓がん診断の世界市場(~2026年) / Global Pancreatic Cancer Diagnostic Market Size, Status and Forecast 2020-2026 / MRC2-11QY04149資料のイメージです。• レポートコード:MRC2-11QY04149
• 出版社/出版日:QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、93ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:ヘルスケア
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は膵臓がん診断のグローバル市場について調査・分析したレポートです。種類別(画像、腫瘍バイオマーカー、生検、その他)市場規模、用途別(病院、診療所、その他)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別膵臓がん診断の競争状況、市場シェア
・世界の膵臓がん診断市場:種類別市場規模 2015年-2020年(画像、腫瘍バイオマーカー、生検、その他)
・世界の膵臓がん診断市場:種類別市場規模予測 2021年-2026年(画像、腫瘍バイオマーカー、生検、その他)
・世界の膵臓がん診断市場:用途別市場規模 2015年-2020年(病院、診療所、その他)
・世界の膵臓がん診断市場:用途別市場規模予測 2021年-2026年(病院、診療所、その他)
・北米の膵臓がん診断市場分析:米国、カナダ
・ヨーロッパの膵臓がん診断市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの膵臓がん診断市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の膵臓がん診断市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの膵臓がん診断市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Roche、GE Healthcare、Siemens、BD、Philips Healthcare、Hitachi Medical、Danaher、Abbott、Canon Medical Systems、Myriad Genetics、Qiagen、Asuragen、BioMarker Strategies
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. This report studies the Pancreatic Cancer Diagnostic market, includes Tumor Biomarker Tests, Imaging, Biopsy and other products.
United States is the largest sales place, with a consumption value market share nearly 32.12% in 2017. Following United States, Europe is the second largest sales place with the consumption market share of 27.65%. Market competition is intense. Roche, GE Healthcare, Siemens, BD, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

Market Analysis and Insights: Global Pancreatic Cancer Diagnostic Market
The global Pancreatic Cancer Diagnostic market size is projected to reach US$ 3887.2 million by 2026, from US$ 2561.3 million in 2020, at a CAGR of 7.2% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pancreatic Cancer Diagnostic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pancreatic Cancer Diagnostic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pancreatic Cancer Diagnostic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pancreatic Cancer Diagnostic market.

Global Pancreatic Cancer Diagnostic Scope and Market Size
Pancreatic Cancer Diagnostic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pancreatic Cancer Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Imaging
Tumor Biomarker
Biopsy
Other

Market segment by Application, split into
Hospitals
Clinics
Others

Based on regional and country-level analysis, the Pancreatic Cancer Diagnostic market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Pancreatic Cancer Diagnostic market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Roche
GE Healthcare
Siemens
BD
Philips Healthcare
Hitachi Medical
Danaher
Abbott
Canon Medical Systems
Myriad Genetics
Qiagen

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pancreatic Cancer Diagnostic Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Imaging
1.2.3 Tumor Biomarker
1.2.4 Biopsy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Pancreatic Cancer Diagnostic Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Pancreatic Cancer Diagnostic Market Perspective (2015-2026)
2.2 Global Pancreatic Cancer Diagnostic Growth Trends by Regions
2.2.1 Pancreatic Cancer Diagnostic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Pancreatic Cancer Diagnostic Historic Market Share by Regions (2015-2020)
2.2.3 Pancreatic Cancer Diagnostic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Pancreatic Cancer Diagnostic Players by Market Size
3.1.1 Global Top Pancreatic Cancer Diagnostic Players by Revenue (2015-2020)
3.1.2 Global Pancreatic Cancer Diagnostic Revenue Market Share by Players (2015-2020)
3.2 Global Pancreatic Cancer Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pancreatic Cancer Diagnostic Revenue
3.4 Global Pancreatic Cancer Diagnostic Market Concentration Ratio
3.4.1 Global Pancreatic Cancer Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pancreatic Cancer Diagnostic Revenue in 2019
3.5 Key Players Pancreatic Cancer Diagnostic Area Served
3.6 Key Players Pancreatic Cancer Diagnostic Product Solution and Service
3.7 Date of Enter into Pancreatic Cancer Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Pancreatic Cancer Diagnostic Breakdown Data by Type (2015-2026)
4.1 Global Pancreatic Cancer Diagnostic Historic Market Size by Type (2015-2020)
4.2 Global Pancreatic Cancer Diagnostic Forecasted Market Size by Type (2021-2026)

5 Pancreatic Cancer Diagnostic Breakdown Data by Application (2015-2026)
5.1 Global Pancreatic Cancer Diagnostic Historic Market Size by Application (2015-2020)
5.2 Global Pancreatic Cancer Diagnostic Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Pancreatic Cancer Diagnostic Market Size (2015-2026)
6.2 North America Pancreatic Cancer Diagnostic Market Size by Type (2015-2020)
6.3 North America Pancreatic Cancer Diagnostic Market Size by Application (2015-2020)
6.4 North America Pancreatic Cancer Diagnostic Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Pancreatic Cancer Diagnostic Market Size (2015-2026)
7.2 Europe Pancreatic Cancer Diagnostic Market Size by Type (2015-2020)
7.3 Europe Pancreatic Cancer Diagnostic Market Size by Application (2015-2020)
7.4 Europe Pancreatic Cancer Diagnostic Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Pancreatic Cancer Diagnostic Market Size (2015-2026)
8.2 China Pancreatic Cancer Diagnostic Market Size by Type (2015-2020)
8.3 China Pancreatic Cancer Diagnostic Market Size by Application (2015-2020)
8.4 China Pancreatic Cancer Diagnostic Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Pancreatic Cancer Diagnostic Market Size (2015-2026)
9.2 Japan Pancreatic Cancer Diagnostic Market Size by Type (2015-2020)
9.3 Japan Pancreatic Cancer Diagnostic Market Size by Application (2015-2020)
9.4 Japan Pancreatic Cancer Diagnostic Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Pancreatic Cancer Diagnostic Market Size (2015-2026)
10.2 Southeast Asia Pancreatic Cancer Diagnostic Market Size by Type (2015-2020)
10.3 Southeast Asia Pancreatic Cancer Diagnostic Market Size by Application (2015-2020)
10.4 Southeast Asia Pancreatic Cancer Diagnostic Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Pancreatic Cancer Diagnostic Introduction
11.1.4 Roche Revenue in Pancreatic Cancer Diagnostic Business (2015-2020))
11.1.5 Roche Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Details
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Pancreatic Cancer Diagnostic Introduction
11.2.4 GE Healthcare Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.2.5 GE Healthcare Recent Development
11.3 Siemens
11.3.1 Siemens Company Details
11.3.2 Siemens Business Overview
11.3.3 Siemens Pancreatic Cancer Diagnostic Introduction
11.3.4 Siemens Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.3.5 Siemens Recent Development
11.4 BD
11.4.1 BD Company Details
11.4.2 BD Business Overview
11.4.3 BD Pancreatic Cancer Diagnostic Introduction
11.4.4 BD Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.4.5 BD Recent Development
11.5 Philips Healthcare
11.5.1 Philips Healthcare Company Details
11.5.2 Philips Healthcare Business Overview
11.5.3 Philips Healthcare Pancreatic Cancer Diagnostic Introduction
11.5.4 Philips Healthcare Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.5.5 Philips Healthcare Recent Development
11.6 Hitachi Medical
11.6.1 Hitachi Medical Company Details
11.6.2 Hitachi Medical Business Overview
11.6.3 Hitachi Medical Pancreatic Cancer Diagnostic Introduction
11.6.4 Hitachi Medical Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.6.5 Hitachi Medical Recent Development
11.7 Danaher
11.7.1 Danaher Company Details
11.7.2 Danaher Business Overview
11.7.3 Danaher Pancreatic Cancer Diagnostic Introduction
11.7.4 Danaher Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.7.5 Danaher Recent Development
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott Pancreatic Cancer Diagnostic Introduction
11.8.4 Abbott Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.8.5 Abbott Recent Development
11.9 Canon Medical Systems
11.9.1 Canon Medical Systems Company Details
11.9.2 Canon Medical Systems Business Overview
11.9.3 Canon Medical Systems Pancreatic Cancer Diagnostic Introduction
11.9.4 Canon Medical Systems Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.9.5 Canon Medical Systems Recent Development
11.10 Myriad Genetics
11.10.1 Myriad Genetics Company Details
11.10.2 Myriad Genetics Business Overview
11.10.3 Myriad Genetics Pancreatic Cancer Diagnostic Introduction
11.10.4 Myriad Genetics Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
11.10.5 Myriad Genetics Recent Development
11.11 Qiagen
10.11.1 Qiagen Company Details
10.11.2 Qiagen Business Overview
10.11.3 Qiagen Pancreatic Cancer Diagnostic Introduction
10.11.4 Qiagen Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
10.11.5 Qiagen Recent Development
11.12 Asuragen
10.12.1 Asuragen Company Details
10.12.2 Asuragen Business Overview
10.12.3 Asuragen Pancreatic Cancer Diagnostic Introduction
10.12.4 Asuragen Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
10.12.5 Asuragen Recent Development
11.13 BioMarker Strategies
10.13.1 BioMarker Strategies Company Details
10.13.2 BioMarker Strategies Business Overview
10.13.3 BioMarker Strategies Pancreatic Cancer Diagnostic Introduction
10.13.4 BioMarker Strategies Revenue in Pancreatic Cancer Diagnostic Business (2015-2020)
10.13.5 BioMarker Strategies Recent Development

12Analyst’s Viewpoints/Conclusions

13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Pancreatic Cancer Diagnostic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Imaging
Table 4. Key Players of Tumor Biomarker
Table 5. Key Players of Biopsy
Table 6. Key Players of Other
Table 7. Global Pancreatic Cancer Diagnostic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Pancreatic Cancer Diagnostic Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Pancreatic Cancer Diagnostic Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Pancreatic Cancer Diagnostic Market Share by Regions (2015-2020)
Table 11. Global Pancreatic Cancer Diagnostic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Pancreatic Cancer Diagnostic Market Share by Regions (2021-2026)
Table 13. Pancreatic Cancer Diagnostic Market Market Trends
Table 14. Pancreatic Cancer Diagnostic Market Drivers
Table 15. Pancreatic Cancer Diagnostic Market Challenges
Table 16. Pancreatic Cancer Diagnostic Market Restraints
Table 17. Global Pancreatic Cancer Diagnostic Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Pancreatic Cancer Diagnostic Market Share by Players (2015-2020)
Table 19. Global Top Pancreatic Cancer Diagnostic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pancreatic Cancer Diagnostic as of 2019)
Table 20. Global Pancreatic Cancer Diagnostic by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pancreatic Cancer Diagnostic Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Pancreatic Cancer Diagnostic Market Size Share by Type (2015-2020)
Table 26. Global Pancreatic Cancer Diagnostic Revenue Market Share by Type (2021-2026)
Table 27. Global Pancreatic Cancer Diagnostic Market Size Share by Application (2015-2020)
Table 28. Global Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 29. Global Pancreatic Cancer Diagnostic Market Size Share by Application (2021-2026)
Table 30. North America Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Pancreatic Cancer Diagnostic Market Share by Type (2015-2020)
Table 32. North America Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 33. North America Pancreatic Cancer Diagnostic Market Share by Application (2015-2020)
Table 34. North America Pancreatic Cancer Diagnostic Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Pancreatic Cancer Diagnostic Market Share by Country (2015-2020)
Table 36. Europe Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Pancreatic Cancer Diagnostic Market Share by Type (2015-2020)
Table 38. Europe Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 39. Europe Pancreatic Cancer Diagnostic Market Share by Application (2015-2020)
Table 40. Europe Pancreatic Cancer Diagnostic Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Pancreatic Cancer Diagnostic Market Share by Country (2015-2020)
Table 42. China Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 43. China Pancreatic Cancer Diagnostic Market Share by Type (2015-2020)
Table 44. China Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 45. China Pancreatic Cancer Diagnostic Market Share by Application (2015-2020)
Table 46. China Pancreatic Cancer Diagnostic Market Size by Region (US$ Million) (2015-2020)
Table 47. China Pancreatic Cancer Diagnostic Market Share by Region (2015-2020)
Table 48. Japan Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 49. Japan Pancreatic Cancer Diagnostic Market Share by Type (2015-2020)
Table 50. Japan Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 51. Japan Pancreatic Cancer Diagnostic Market Share by Application (2015-2020)
Table 52. Japan Pancreatic Cancer Diagnostic Market Size by Country (US$ Million) (2015-2020)
Table 53. Japan Pancreatic Cancer Diagnostic Market Share by Country (2015-2020)
Table 54. Southeast Asia Pancreatic Cancer Diagnostic Market Size by Type (2015-2020) (US$ Million)
Table 55. Southeast Asia Pancreatic Cancer Diagnostic Market Share by Type (2015-2020)
Table 56. Southeast Asia Pancreatic Cancer Diagnostic Market Size by Application (2015-2020) (US$ Million)
Table 57. Southeast Asia Pancreatic Cancer Diagnostic Market Share by Application (2015-2020)
Table 58. Southeast Asia Pancreatic Cancer Diagnostic Market Size by Country (US$ Million) (2015-2020)
Table 59. Southeast Asia Pancreatic Cancer Diagnostic Market Share by Country (2015-2020)
Table 60. Roche Company Details
Table 61. Roche Business Overview
Table 62. Roche Product
Table 63. Roche Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 64. Roche Recent Development
Table 65. GE Healthcare Company Details
Table 66. GE Healthcare Business Overview
Table 67. GE Healthcare Product
Table 68. GE Healthcare Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 69. GE Healthcare Recent Development
Table 70. Siemens Company Details
Table 71. Siemens Business Overview
Table 72. Siemens Product
Table 73. Siemens Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 74. Siemens Recent Development
Table 75. BD Company Details
Table 76. BD Business Overview
Table 77. BD Product
Table 78. BD Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 79. BD Recent Development
Table 80. Philips Healthcare Company Details
Table 81. Philips Healthcare Business Overview
Table 82. Philips Healthcare Product
Table 83. Philips Healthcare Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 84. Philips Healthcare Recent Development
Table 85. Hitachi Medical Company Details
Table 86. Hitachi Medical Business Overview
Table 87. Hitachi Medical Product
Table 88. Hitachi Medical Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 89. Hitachi Medical Recent Development
Table 90. Danaher Company Details
Table 91. Danaher Business Overview
Table 92. Danaher Product
Table 93. Danaher Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 94. Danaher Recent Development
Table 95. Abbott Business Overview
Table 96. Abbott Product
Table 97. Abbott Company Details
Table 98. Abbott Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 99. Abbott Recent Development
Table 100. Canon Medical Systems Company Details
Table 101. Canon Medical Systems Business Overview
Table 102. Canon Medical Systems Product
Table 103. Canon Medical Systems Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 104. Canon Medical Systems Recent Development
Table 105. Myriad Genetics Company Details
Table 106. Myriad Genetics Business Overview
Table 107. Myriad Genetics Product
Table 108. Myriad Genetics Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 109. Myriad Genetics Recent Development
Table 110. Qiagen Company Details
Table 111. Qiagen Business Overview
Table 112. Qiagen Product
Table 113. Qiagen Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 114. Qiagen Recent Development
Table 115. Asuragen Company Details
Table 116. Asuragen Business Overview
Table 117. Asuragen Product
Table 118. Asuragen Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 119. Asuragen Recent Development
Table 120. BioMarker Strategies Company Details
Table 121. BioMarker Strategies Business Overview
Table 122. BioMarker Strategies Product
Table 123. BioMarker Strategies Revenue in Pancreatic Cancer Diagnostic Business (2015-2020) (US$ Million)
Table 124. BioMarker Strategies Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pancreatic Cancer Diagnostic Market Share by Type: 2020 VS 2026
Figure 2. Imaging Features
Figure 3. Tumor Biomarker Features
Figure 4. Biopsy Features
Figure 5. Other Features
Figure 6. Global Pancreatic Cancer Diagnostic Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Pancreatic Cancer Diagnostic Report Years Considered
Figure 11. Global Pancreatic Cancer Diagnostic Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Pancreatic Cancer Diagnostic Market Share by Regions: 2020 VS 2026
Figure 13. Global Pancreatic Cancer Diagnostic Market Share by Regions (2021-2026)
Figure 14. Global Pancreatic Cancer Diagnostic Market Share by Players in 2019
Figure 15. Global Top Pancreatic Cancer Diagnostic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pancreatic Cancer Diagnostic as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Pancreatic Cancer Diagnostic Revenue in 2019
Figure 17. North America Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Pancreatic Cancer Diagnostic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. Roche Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 45. GE Healthcare Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 46. Siemens Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 47. BD Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 48. Philips Healthcare Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 49. Hitachi Medical Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 50. Danaher Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 51. Abbott Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 52. Canon Medical Systems Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 53. Myriad Genetics Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 54. Qiagen Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 55. Asuragen Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 56. BioMarker Strategies Revenue Growth Rate in Pancreatic Cancer Diagnostic Business (2015-2020)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed